Boston Scientific Corp on Monday said it has temporarily stopped selling a newer version of its Watchman atrial fibrillation treatment in Europe due to a higher-than-expected rate of embolisms associated with the implant.
The FLX model, launched in some European markets in November, is a second-generation version of the Watchman device sold in the United States.
The implant is designed to prevent strokes in patients with a form of atrial fibrillation, or irregular heartbeat.
The FLX model, launched in some European markets in November, is a second-generation version of the Watchman device sold in the United States.
The implant is designed to prevent strokes in patients with a form of atrial fibrillation, or irregular heartbeat.
